---
title: "Jinhe Biotechnology: Net profit expected to increase by 40%-55% in the first half of the year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/248283054.md"
description: "Jinhe Biotechnology expects its net profit in the first half of 2025 to reach between 127 million and 141 million yuan, a year-on-year increase of 40%-55%. Sales of veterinary chemical drugs continue to grow, especially with good performance in overseas markets; after the production of the sixth phase project, output has increased to meet supply demands and enhance profits. In addition, the agricultural products processing sector has also contributed to performance due to the decline in corn prices"
datetime: "2025-07-13T08:26:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/248283054.md)
  - [en](https://longbridge.com/en/news/248283054.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/248283054.md)
generator: "portal-rs"
---

# Jinhe Biotechnology: Net profit expected to increase by 40%-55% in the first half of the year

Jinhe Biotechnology announced that it expects the net profit attributable to shareholders of the listed company for the first half of 2025 to be between 127 million yuan and 141 million yuan, an increase of 40%-55% compared to the same period last year. During the reporting period, the sales of the veterinary chemical drug sector continued to improve, with sales of major products, such as chlortetracycline, increasing in both domestic and overseas markets, especially with continued growth in overseas sales; the production increase after the completion of the sixth phase project ensured supply demand and created more profits. The agricultural product processing sector also contributed to the overall performance improvement due to the decline in the price of the main raw material, corn

### Related Stocks

- [002688.CN](https://longbridge.com/en/quote/002688.CN.md)

## Related News & Research

- [NorthCore Life’s LotosPFA wins China NMPA approval for nano pulsed-field ablation system](https://longbridge.com/en/news/297260650.md)
- [Beijing State-Owned Capital Operation targets “full-cycle, multi-asset” fund platform in 15th Five-Year plan draft](https://longbridge.com/en/news/297650698.md)
- [BW ESS buys 126-MW Spanish battery storage projects from Navacant](https://longbridge.com/en/news/297744603.md)
- [Motus FY26 earnings per share rise 19% to 1,753 cents; revenue climbs 1% to ZAR 113.55 billion](https://longbridge.com/en/news/297734398.md)
- [Xinhua Pharma unit Xincat’s azithromycin tablets pass China generic consistency evaluation](https://longbridge.com/en/news/297485179.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**